282 related articles for article (PubMed ID: 33089525)
21. Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL.
Reiff SD; Muhowski EM; Guinn D; Lehman A; Fabian CA; Cheney C; Mantel R; Smith L; Johnson AJ; Young WB; Johnson AR; Liu L; Byrd JC; Woyach JA
Blood; 2018 Sep; 132(10):1039-1049. PubMed ID: 30018078
[TBL] [Abstract][Full Text] [Related]
22. The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation.
Reiff SD; Mantel R; Smith LL; Greene JT; Muhowski EM; Fabian CA; Goettl VM; Tran M; Harrington BK; Rogers KA; Awan FT; Maddocks K; Andritsos L; Lehman AM; Sampath D; Lapalombella R; Eathiraj S; Abbadessa G; Schwartz B; Johnson AJ; Byrd JC; Woyach JA
Cancer Discov; 2018 Oct; 8(10):1300-1315. PubMed ID: 30093506
[TBL] [Abstract][Full Text] [Related]
23. Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors.
Wang E; Mi X; Thompson MC; Montoya S; Notti RQ; Afaghani J; Durham BH; Penson A; Witkowski MT; Lu SX; Bourcier J; Hogg SJ; Erickson C; Cui D; Cho H; Singer M; Totiger TM; Chaudhry S; Geyer M; Alencar A; Linley AJ; Palomba ML; Coombs CC; Park JH; Zelenetz A; Roeker L; Rosendahl M; Tsai DE; Ebata K; Brandhuber B; Hyman DM; Aifantis I; Mato A; Taylor J; Abdel-Wahab O
N Engl J Med; 2022 Feb; 386(8):735-743. PubMed ID: 35196427
[TBL] [Abstract][Full Text] [Related]
24. Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma.
Zhang SQ; Smith SM; Zhang SY; Lynn Wang Y
Br J Haematol; 2015 Aug; 170(4):445-56. PubMed ID: 25858358
[TBL] [Abstract][Full Text] [Related]
25. Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies.
Kapoor I; Li Y; Sharma A; Zhu H; Bodo J; Xu W; Hsi ED; Hill BT; Almasan A
Cell Death Dis; 2019 Dec; 10(12):924. PubMed ID: 31801949
[TBL] [Abstract][Full Text] [Related]
26. The Phospholipase Cγ2 Mutants R665W and L845F Identified in Ibrutinib-resistant Chronic Lymphocytic Leukemia Patients Are Hypersensitive to the Rho GTPase Rac2 Protein.
Walliser C; Hermkes E; Schade A; Wiese S; Deinzer J; Zapatka M; Désiré L; Mertens D; Stilgenbauer S; Gierschik P
J Biol Chem; 2016 Oct; 291(42):22136-22148. PubMed ID: 27542411
[TBL] [Abstract][Full Text] [Related]
27. An evaluation of zanubrutinib, a BTK inhibitor, for the treatment of chronic lymphocytic leukemia.
Geethakumari PR; Awan F
Expert Rev Hematol; 2020 Oct; 13(10):1039-1046. PubMed ID: 32869675
[TBL] [Abstract][Full Text] [Related]
28. Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside.
Wu J; Zhang M; Liu D
Oncotarget; 2017 Jan; 8(4):7201-7207. PubMed ID: 27776353
[TBL] [Abstract][Full Text] [Related]
29. Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance.
Naeem A; Utro F; Wang Q; Cha J; Vihinen M; Martindale S; Zhou Y; Ren Y; Tyekucheva S; Kim AS; Fernandes SM; Saksena G; Rhrissorrakrai K; Levovitz C; Danysh BP; Slowik K; Jacobs RA; Davids MS; Lederer JA; Zain R; Smith CIE; Leshchiner I; Parida L; Getz G; Brown JR
Blood Adv; 2023 May; 7(9):1929-1943. PubMed ID: 36287227
[TBL] [Abstract][Full Text] [Related]
30. Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation.
Buhimschi AD; Armstrong HA; Toure M; Jaime-Figueroa S; Chen TL; Lehman AM; Woyach JA; Johnson AJ; Byrd JC; Crews CM
Biochemistry; 2018 Jul; 57(26):3564-3575. PubMed ID: 29851337
[TBL] [Abstract][Full Text] [Related]
31. The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy.
Landau DA; Sun C; Rosebrock D; Herman SEM; Fein J; Sivina M; Underbayev C; Liu D; Hoellenriegel J; Ravichandran S; Farooqui MZH; Zhang W; Cibulskis C; Zviran A; Neuberg DS; Livitz D; Bozic I; Leshchiner I; Getz G; Burger JA; Wiestner A; Wu CJ
Nat Commun; 2017 Dec; 8(1):2185. PubMed ID: 29259203
[TBL] [Abstract][Full Text] [Related]
32. Pirtobrutinib inhibits wild-type and mutant Bruton's tyrosine kinase-mediated signaling in chronic lymphocytic leukemia.
Aslan B; Kismali G; Iles LR; Manyam GC; Ayres ML; Chen LS; Gagea M; Bertilaccio MTS; Wierda WG; Gandhi V
Blood Cancer J; 2022 May; 12(5):80. PubMed ID: 35595730
[TBL] [Abstract][Full Text] [Related]
33. Management of patients with chronic lymphocytic leukemia at high risk of relapse on ibrutinib therapy.
Ayed AO; Parikh SA
Leuk Lymphoma; 2018 Oct; 59(10):2287-2296. PubMed ID: 29115892
[TBL] [Abstract][Full Text] [Related]
34. BTK-independent regulation of calcium signalling downstream of the B-cell receptor in malignant B-cells.
Arthur R; Wathen A; Lemm EA; Stevenson FK; Forconi F; Linley AJ; Steele AJ; Packham G; Valle-Argos B
Cell Signal; 2022 Aug; 96():110358. PubMed ID: 35597428
[TBL] [Abstract][Full Text] [Related]
35. [Research Progress of Targeted Therapy for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma --Review].
Chen D; Wang MY; Tian C
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):643-646. PubMed ID: 38660880
[TBL] [Abstract][Full Text] [Related]
36. MALT1 Inhibition Is Efficacious in Both Naïve and Ibrutinib-Resistant Chronic Lymphocytic Leukemia.
Saba NS; Wong DH; Tanios G; Iyer JR; Lobelle-Rich P; Dadashian EL; Liu D; Fontan L; Flemington EK; Nichols CM; Underbayev C; Safah H; Melnick A; Wiestner A; Herman SEM
Cancer Res; 2017 Dec; 77(24):7038-7048. PubMed ID: 28993409
[TBL] [Abstract][Full Text] [Related]
37. Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells.
Till KJ; Pettitt AR; Slupsky JR
J Immunol; 2015 Mar; 194(5):2439-46. PubMed ID: 25632006
[TBL] [Abstract][Full Text] [Related]
38. Role of Bruton's tyrosine kinase in B cells and malignancies.
Pal Singh S; Dammeijer F; Hendriks RW
Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
[TBL] [Abstract][Full Text] [Related]
39. Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition.
Burger JA; Landau DA; Taylor-Weiner A; Bozic I; Zhang H; Sarosiek K; Wang L; Stewart C; Fan J; Hoellenriegel J; Sivina M; Dubuc AM; Fraser C; Han Y; Li S; Livak KJ; Zou L; Wan Y; Konoplev S; Sougnez C; Brown JR; Abruzzo LV; Carter SL; Keating MJ; Davids MS; Wierda WG; Cibulskis K; Zenz T; Werner L; Dal Cin P; Kharchencko P; Neuberg D; Kantarjian H; Lander E; Gabriel S; O'Brien S; Letai A; Weitz DA; Nowak MA; Getz G; Wu CJ
Nat Commun; 2016 May; 7():11589. PubMed ID: 27199251
[TBL] [Abstract][Full Text] [Related]
40. Kinase-deficient BTK mutants confer ibrutinib resistance through activation of the kinase HCK.
Dhami K; Chakraborty A; Gururaja TL; Cheung LW; Sun C; DeAnda F; Huang X
Sci Signal; 2022 May; 15(736):eabg5216. PubMed ID: 35639855
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]